Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Radiotherapy and Imaging
  • View item
  • Home
  • ICR Divisions
  • Radiotherapy and Imaging
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Acoustic Cluster Therapy (ACT) enhances the therapeutic efficacy of paclitaxel and Abraxane® for treatment of human prostate adenocarcinoma in mice.

Thumbnail
View/Open
Published version (951.4Kb)
Date
2016-08
ICR Author
Bamber, Jeffrey
Author
van Wamel, A
Sontum, PC
Healey, A
Kvåle, S
Bush, N
Bamber, J
de Lange Davies, C
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Acoustic cluster therapy (ACT) is a novel approach for ultrasound mediated, targeted drug delivery. In the current study, we have investigated ACT in combination with paclitaxel and Abraxane® for treatment of a subcutaneous human prostate adenocarcinoma (PC3) in mice. In combination with paclitaxel (12mg/kg given i.p.), ACT induced a strong increase in therapeutic efficacy; 120days after study start, 42% of the animals were in stable, complete remission vs. 0% for the paclitaxel only group and the median survival was increased by 86%. In combination with Abraxane® (12mg paclitaxel/kg given i.v.), ACT induced a strong increase in the therapeutic efficacy; 60days after study start 100% of the animals were in stable, remission vs. 0% for the Abraxane® only group, 120days after study start 67% of the animals were in stable, complete remission vs. 0% for the Abraxane® only group. For the ACT+Abraxane group 100% of the animals were alive after 120days vs. 0% for the Abraxane® only group. Proof of concept for Acoustic Cluster Therapy has been demonstrated; ACT markedly increases the therapeutic efficacy of both paclitaxel and Abraxane® for treatment of human prostate adenocarcinoma in mice.
URI
https://repository.icr.ac.uk/handle/internal/550
DOI
https://doi.org/10.1016/j.jconrel.2016.06.018
Collections
  • Radiotherapy and Imaging
Subject
Cell Line, Tumor
Animals
Humans
Mice
Prostatic Neoplasms
Paclitaxel
Antineoplastic Combined Chemotherapy Protocols
Drug Delivery Systems
Male
Drug Liberation
Ultrasonic Waves
Albumin-Bound Paclitaxel
Research team
Ultrasound & Optical Imaging
Language
eng
Date accepted
2016-06-09
License start date
2016-08
Citation
Journal of controlled release : official journal of the Controlled Release Society, 2016, 236 pp. 15 - 21

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.